Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Current Deferred Tax Assets (2016 - 2022)

Usana Health Sciences (USNA) has disclosed Current Deferred Tax Assets for 10 consecutive years, with $2.3 million as the latest value for Q1 2022.

  • Quarterly Current Deferred Tax Assets rose 9.34% to $2.3 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Jan 2022, up 9.34% year-over-year, with the annual reading at $2.3 million for FY2022, 9.34% up from the prior year.
  • Current Deferred Tax Assets for Q1 2022 was $2.3 million at Usana Health Sciences, up from $2.1 million in the prior quarter.
  • The five-year high for Current Deferred Tax Assets was $2.3 million in Q1 2022, with the low at $1.7 million in Q4 2019.
  • Average Current Deferred Tax Assets over 4 years is $2.0 million, with a median of $2.1 million recorded in 2018.
  • The sharpest move saw Current Deferred Tax Assets crashed 32.24% in 2018, then increased 24.24% in 2021.
  • Over 4 years, Current Deferred Tax Assets stood at $2.0 million in 2018, then dropped by 18.05% to $1.7 million in 2019, then rose by 24.24% to $2.1 million in 2021, then rose by 9.34% to $2.3 million in 2022.
  • According to Business Quant data, Current Deferred Tax Assets over the past three periods came in at $2.3 million, $2.1 million, and $1.7 million for Q1 2022, Q1 2021, and Q4 2019 respectively.